Tags

Type your tag names separated by a space and hit enter

Effect of entacapone on plasma homocysteine levels in Parkinson's disease patients.
Neurol Sci. 2010 Oct; 31(5):565-9.NS

Abstract

Peripheral metabolism of L-DOPA via enzyme catechol-O-methyltransferase (COMT) is one of the possible sources of homocysteine (HCY). The aim of this study was to assess plasma HCY levels in L-DOPA-treated Parkinson's disease (PD) patients and its influence by adding the inhibitor COMT (entacapone). Patients were divided into two groups: (1) patients long term treated with L-DOPA but were naïve to entacapone, (2) L-DOPA naïve patients, in whom a combined treatment with L-DOPA and entacapone was started. The HCY levels were higher in Group 1 than in Group 2. No statistically significant changes of HCY concentrations were found in both patient groups after adding entacapone to their L-DOPA treatments. Results of this study confirm that patients treated with L-DOPA for a long term have increased plasma HCY concentrations. We believe combined L-DOPA and entacapone therapy could be a possible protective mechanism against hyperhomocysteinemia in early PD.

Authors+Show Affiliations

Department of Neurology, University Hospital and Palacký University Medical School, I. P. Pavlova 6, 77520, Olomouc, Czech Republic. nevrly.martin@post.czNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

20464572

Citation

Nevrly, Martin, et al. "Effect of Entacapone On Plasma Homocysteine Levels in Parkinson's Disease Patients." Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, vol. 31, no. 5, 2010, pp. 565-9.
Nevrly M, Kanovsky P, Vranova H, et al. Effect of entacapone on plasma homocysteine levels in Parkinson's disease patients. Neurol Sci. 2010;31(5):565-9.
Nevrly, M., Kanovsky, P., Vranova, H., Langova, K., & Hlustik, P. (2010). Effect of entacapone on plasma homocysteine levels in Parkinson's disease patients. Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 31(5), 565-9. https://doi.org/10.1007/s10072-010-0262-0
Nevrly M, et al. Effect of Entacapone On Plasma Homocysteine Levels in Parkinson's Disease Patients. Neurol Sci. 2010;31(5):565-9. PubMed PMID: 20464572.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of entacapone on plasma homocysteine levels in Parkinson's disease patients. AU - Nevrly,Martin, AU - Kanovsky,Petr, AU - Vranova,Hana, AU - Langova,Katerina, AU - Hlustik,Petr, Y1 - 2010/05/13/ PY - 2009/02/02/received PY - 2010/03/31/accepted PY - 2010/5/14/entrez PY - 2010/5/14/pubmed PY - 2011/1/8/medline SP - 565 EP - 9 JF - Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology JO - Neurol Sci VL - 31 IS - 5 N2 - Peripheral metabolism of L-DOPA via enzyme catechol-O-methyltransferase (COMT) is one of the possible sources of homocysteine (HCY). The aim of this study was to assess plasma HCY levels in L-DOPA-treated Parkinson's disease (PD) patients and its influence by adding the inhibitor COMT (entacapone). Patients were divided into two groups: (1) patients long term treated with L-DOPA but were naïve to entacapone, (2) L-DOPA naïve patients, in whom a combined treatment with L-DOPA and entacapone was started. The HCY levels were higher in Group 1 than in Group 2. No statistically significant changes of HCY concentrations were found in both patient groups after adding entacapone to their L-DOPA treatments. Results of this study confirm that patients treated with L-DOPA for a long term have increased plasma HCY concentrations. We believe combined L-DOPA and entacapone therapy could be a possible protective mechanism against hyperhomocysteinemia in early PD. SN - 1590-3478 UR - https://www.unboundmedicine.com/medline/citation/20464572/Effect_of_entacapone_on_plasma_homocysteine_levels_in_Parkinson's_disease_patients_ L2 - https://link.springer.com/10.1007/s10072-010-0262-0 DB - PRIME DP - Unbound Medicine ER -